📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: 4-Antibody

1.1 - Company Overview

4-Antibody Logo

4-Antibody

Headquarter: Switzerland
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of a human antibody drug-discovery platform focused on immuno-oncology, leveraging Retrocyte Display to generate therapeutic antibody candidates from human libraries expressed in mammalian B-lineage lymphocytes, and developer of a pipeline including Botensilimab (CTLA-4), Balstilimab (PD-1), Zalifrelimab (CTLA-4), AGEN2373 (anti-CD137), AGEN1571 (ILT-2) and ILT4 antagonists, with ongoing clinical trials across multiple cancers.

Products and services

  • Balstilimab: PD-1 inhibitor (backbone) that blocks PD-1 to reactivate exhausted T cells and restore cancer-fighting function, engineered as a foundational agent for combination immuno-oncology trials
  • Botensilimab: A CTLA-4 antibody with a modified Fc region (phase 2) that activates T cells, eliminates regulatory T cells, and establishes memory cells, tested in melanoma, MSS colorectal, pancreatic cancers
  • Zalifrelimab: CTLA-4 antagonist (antagonist) that blocks CTLA-4 and binding partners to promote T cell activation and tumor-killing, with demonstrated efficacy in multiple indications, including cervical cancer

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to 4-Antibody

Valo Therapeutics Logo

Valo Therapeutics

HQ: Finland Website
  • Description: Provider of immuno-oncology platforms developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. Offerings include PeptiCRAd (oncolytic adenoviruses plus tumor-specific peptides), PeptiENV (oncolytic enveloped viruses with peptides), PeptiVAX (peptide-based cancer vaccines), PeptiBAC (bacteria delivering tumor peptides), and PeptiCHIP (microchip-based tumor neoantigen identification).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Valo Therapeutics company profile →
Vaccinex Logo

Vaccinex

HQ: United States Website
  • Description: Provider of therapeutic antibody discovery and development focused on neurodegeneration, oncology and autoimmune diseases. Offers Pepinemab, a monoclonal antibody targeting SEMA4D in clinical trials for cancers, Huntington's and Alzheimer's; ActivMAb, a platform for antibody discovery against complex antigens; and VX5/5261, a CXCL13-targeting antibody in preclinical development for rheumatoid arthritis and multiple sclerosis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Vaccinex company profile →
Carisma Therapeutics Logo

Carisma Therapeutics

HQ: United States Website
  • Description: Provider of chimeric antigen receptor macrophage therapies for solid tumors, including CT-0525, an ex vivo gene-modified autologous CAR-Monocyte therapy targeting HER2-overexpressing solid tumors in Phase 1, and in vivo macrophage-targeted therapies for solid tumors via a partnership with Moderna, with a lead candidate targeting an unspecified antigen; also pursuing early R&D in liver fibrosis using its macrophage and monocyte engineering platform.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Carisma Therapeutics company profile →
Xencor Logo

Xencor

HQ: United States Website
  • Description: Provider of monoclonal antibody therapeutics and an antibody engineering platform. The XmAb Protein Engineering Platform improves potency, half-life and stability via Fc-domain engineering. Offerings include Monjuvi (tafasitamab-cxix) with lenalidomide for relapsed or refractory diffuse large B-cell lymphoma, and clinical bispecifics vudalimab, XmAb819, XmAb808 and XmAb541 for cancer and in autoimmune, asthma and allergic diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Xencor company profile →
Be Bio Logo

Be Bio

HQ: United States Website
  • Description: Provider of engineered B cell medicines for serious genetic diseases, including BE-101 to produce active and sustained Factor IX for Hemophilia B. Offers BCMs engineered to produce highly active and sustained antitumor biologics for cancer, and BCMs designed to produce therapeutic proteins for genetic and rare diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Be Bio company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for 4-Antibody

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to 4-Antibody

2.2 - Growth funds investing in similar companies to 4-Antibody

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for 4-Antibody

4.2 - Public trading comparable groups for 4-Antibody

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to 4-Antibody

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About 4-Antibody

What does 4-Antibody do?

4-Antibody is a provider of a human antibody drug-discovery platform focused on immuno-oncology, leveraging Retrocyte Display to generate therapeutic antibody candidates from human libraries expressed in mammalian B-lineage lymphocytes, and developer of a pipeline including Botensilimab (CTLA-4), Balstilimab (PD-1), Zalifrelimab (CTLA-4), AGEN2373 (anti-CD137), AGEN1571 (ILT-2) and ILT4 antagonists, with ongoing clinical trials across multiple cancers.

Who are 4-Antibody's competitors?

4-Antibody's competitors and similar companies include Valo Therapeutics, Vaccinex, Carisma Therapeutics, Xencor, and Be Bio.

Where is 4-Antibody headquartered?

4-Antibody is headquartered in Switzerland.

How many employees does 4-Antibody have?

4-Antibody has 1,000 employees 🔒.

When was 4-Antibody founded?

4-Antibody was founded in 2010 🔒.

What sector and industry vertical is 4-Antibody in?

4-Antibody is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for 4-Antibody

Who are the top strategic acquirers in 4-Antibody's sector and industry

Top strategic M&A buyers and acquirers in 4-Antibody's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for 4-Antibody?

Top strategic M&A buyers groups and sectors for 4-Antibody include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in 4-Antibody's sector and industry vertical

Which are the top PE firms investing in 4-Antibody's sector and industry vertical?

Top PE firms investing in 4-Antibody's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in 4-Antibody's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in 4-Antibody's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in 4-Antibody's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to 4-Antibody include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in 4-Antibody's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for 4-Antibody?

The key public trading comparables and valuation benchmarks for 4-Antibody include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for 4-Antibody for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for 4-Antibody with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in 4-Antibody's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for 4-Antibody with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in 4-Antibody's' sector and industry vertical?

Access recent funding rounds and capital raises in 4-Antibody's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for 4-Antibody